TWD 13.85
(-0.72%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 37.4 Million TWD | 27.51% |
2022 | 29.33 Million TWD | -42.04% |
2021 | 50.61 Million TWD | 38.31% |
2020 | 36.59 Million TWD | -33.39% |
2019 | 54.93 Million TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 30.16 Million TWD | -19.34% |
2024 Q2 | 30.16 Million TWD | 0.0% |
2023 FY | 37.4 Million TWD | 27.51% |
2023 Q2 | 28.56 Million TWD | 1.01% |
2023 Q1 | 28.28 Million TWD | -3.58% |
2023 Q3 | 37.11 Million TWD | 29.93% |
2023 Q4 | 37.4 Million TWD | 0.77% |
2022 Q3 | 29.33 Million TWD | 0.0% |
2022 Q4 | 29.33 Million TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Allied Biotech Corporation | 910.11 Million TWD | 95.891% |
GeneFerm Biotechnology Co., Ltd. | 282.53 Million TWD | 86.762% |
Easywell Biomedicals, Inc. | 589.98 Million TWD | 93.661% |
TTY Biopharm Company Limited | 3.36 Billion TWD | 98.89% |
Synmosa Biopharma Corporation | 3.62 Billion TWD | 98.969% |
Orient EuroPharma Co., Ltd. | 6.64 Billion TWD | 99.438% |
Center Laboratories, Inc. | 6.78 Billion TWD | 99.449% |
Tien Liang BioTech Co., Ltd. | 161.05 Million TWD | 76.777% |
Orient Pharma Co., Ltd. | 892.18 Million TWD | 95.808% |
InnoPharmax Inc. | 48.64 Million TWD | 23.121% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 320.99 Million TWD | 88.348% |
Excelsior Biopharma Inc. | 472.87 Million TWD | 92.091% |
DV Biomed Co., Ltd. | 765.87 Million TWD | 95.117% |
Foresee Pharmaceuticals Co., Ltd. | 616.93 Million TWD | 93.938% |
Handa Pharmaceuticals, Inc. | 280.88 Million TWD | 86.684% |
Anxo Pharmaceutical Co., Ltd. | 1.01 Billion TWD | 96.316% |
Alar Pharmaceuticals Inc. | 76.08 Million TWD | 50.846% |
Winston Medical Supply Co., Ltd. | 373.87 Million TWD | 89.996% |
Mercury Biopharmaceutical Corporation | 49.72 Million TWD | 24.778% |
Bioray Biotech Co., Ltd | 108.75 Million TWD | 65.609% |
TSH Biopharm Corporation Limited | 133.62 Million TWD | 72.011% |